Asset Details
Do you wish to reserve the book?
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Do you wish to request the book?
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
2012
Overview
The objective of this study was to explore the association between use of metformin or other antidiabetic drugs, diabetes, and the risk of pancreatic cancer.
We conducted a case-control study using the UK-based General Practice Research Database (GPRD). Cases had a first-time diagnosis of pancreatic cancer, and six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the GPRD before the index date. Results were further adjusted in multivariate logistic regression analyses for potential confounders such as body mass index, smoking, alcohol consumption, and diabetes duration.
In all, 2,763 case patients with a recorded diagnosis of pancreatic cancer were identified. Mean age ± s.d. was 69.5 ± 11.0 years. Long-term use (≥ 30 prescriptions) of metformin was not associated with a materially altered risk of pancreatic cancer (adjusted odds ratio (adj. OR): 0.87, 95% confidence interval (CI): 0.59-1.29), but there was a suggestion of effect modification by gender, as long-term use of metformin was linked to a decreased risk in women (adj. OR: 0.43, 95% CI: 0.23-0.80). Both use of sulfonylureas (≥ 30 prescriptions, adj. OR: 1.90, 95% CI: 1.32-2.74) and of insulin (≥ 40 prescriptions, adj. OR: 2.29, 95% CI: 1.34-3.92) were associated with an increased risk of pancreatic cancer.
Use of metformin was associated with a decreased risk of pancreatic cancer in women only, whereas use of sulfonylureas and of insulin was associated with an increased risk of pancreatic cancer.
Publisher
Nature Publishing Group,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subject
/ Aged
/ Biological and medical sciences
/ Diabetes Mellitus - drug therapy
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Hypoglycemic Agents - adverse effects
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Pancreatic Neoplasms - chemically induced
/ Risk
/ Sulfonylurea Compounds - adverse effects
/ Tumors
